WillItSurvive
Medical technology and health companies · subsidiary of CHA Hospital & Bio Group · South Korea

Kakao Healthcare

kakaohealthcare.com ↗

Consumer app for diabetes and weight coaching, now pivoting to hospital software.

Losing its protection
Assessed 30 July 2026 · Evidence as of 30 July 2026
The structural protection is eroding.
On the recordSince 30 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: July 2026 PASTA 'full agentic AI' update ships
The call

Kakao Healthcare lost its parent's backing, runs a loss-making app built on borrowed AI, and is betting a new hospital pivot beats CHA Bio's patience.

Kakao Healthcare makes a smartphone app called PASTA that coaches people on managing long-term health problems using AI. The app is not working: it lost money equal to 1.7 times its total sales last year, and those losses are getting bigger. The main problem is that big tech companies like Google, OpenAI, and Amazon are building their own health AI tools that are much more powerful, and Kakao's app is just a thin layer on top of Google's technology anyway. The company was recently handed off to a medical company called CHA Bio Group, which is also losing money, so watch whether CHA keeps paying to keep Kakao Healthcare alive or decides to shut it down or sell it off in the next few quarters.

Why
01
AI pressure: Google Gemini / OpenAI health agents. PASTA runs on Google's Gemini, so Google or OpenAI could ship their own coaching agent and cut Kakao Healthcare out entirely. Could AI do the core job? Yes, likely.
02
Bigger players: Naver. Naver is pushing into healthcare B2B software, threatening Kakao Healthcare's new hospital pivot before it gets traction. Could a giant copy it? Yes, easily.
03
What protects it. CHA Bio Group's hospital network gives the new hospital software pivot a captive first customer, if CHA keeps funding it.
What would change this call
CHA Biotech Q2-Q4 2026 filings show consolidated operating loss trend. Widening losses would signal CHA funding pullback and forced wind-down risk.
Completion and terms of the ~₩90bn rights offering by H1 2026. Shows whether Kakao and external investors still back the company financially.
B2H/EHR hospital adoption inside and outside CHA network by Q3 2026. Tests whether the pivot creates real switching-cost lock-in or stalls.
Key numbers
  • FY2025 revenue ₩23.1bn, missed ₩27-30bn target (2025-12-31)
  • FY2025 operating loss ₩39.2bn, up 12.4% y/y (2025-12-31)
  • CHA Biotech Q1 2026 loss doubled to ₩30.7bn (2026-03-31)
Named risks
  • FY2025 operating loss of ₩39.2bn widened 12.4% y/y despite revenue growth. Severity: high
  • Parent CHA Biotech's consolidated losses doubled to ₩30.7bn in Q1 2026 after absorbing the company. Severity: high
  • Core PASTA product is a thin Gemini wrapper labeled wellness, not medical device, with no regulatory moat. Severity: medium
  • Kakao Corp reported internal turmoil and app ranking losses may reduce parent support. Severity: medium
  • Unresolved 2023 IP dispute with Dr.Diary could resurface amid market consolidation. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Dr.DiarycontestingAccused Kakao Healthcare of copying its blood-sugar app model in a 2023-04-11 dispute
NavercontestingPursuing a B2B-focused healthcare strategy against Kakao's consumer app, per 2026-02-11 report
OpenAIgaining onNamed as a frontier AI entrant racing into healthcare, framing Kakao as reactive, 2026-02-11
Amazongaining onCited alongside OpenAI as global healthcare AI entrant pressuring Korean players, 2026-02-11
CHA Hospital and Bio Groupgaining onTook management control from Kakao in Nov 2025 after chronic losses, now sets strategy
Questions people ask
Is Kakao Healthcare profitable?
No. Kakao Healthcare posted an operating loss of ₩39.2 billion in FY2025 on revenue of ₩23.1 billion, meaning losses exceeded revenue by roughly 1.7 times. The loss widened 12.4 percent year over year, and CHA Biotech's Q1 2026 consolidated operating loss more than doubled after absorbing Kakao Healthcare's numbers, per a 2026-05-15 report.
Who owns Kakao Healthcare now?
Kakao Corp lost management control in November 2025 when it sold a majority stake to CHA Hospital and Bio Group. Post-deal ownership was CHA Cares 47.03 percent, CHA AI Healthcare 36.58 percent, and Kakao 16.39 percent, with a rights offering expected to leave Kakao around 30 percent by H1 2026.
Could AI replace Kakao Healthcare's PASTA app?
PASTA's core function, pattern recognition over glucose, weight, sleep and blood pressure data, runs on Google's Gemini model and is explicitly labeled a wellness product, not a medical device. With no exclusive data or regulatory moat, frontier labs like OpenAI and Amazon could replicate similar coaching features, per a 2026-02-11 industry report.
Who is Kakao Healthcare's biggest competitor?
Dr.Diary, a Seoul-based blood-glucose management startup founded in 2017, is the closest direct rival and publicly accused Kakao Healthcare of copying its model in 2023. Naver is also pursuing a competing B2B healthcare strategy, while OpenAI and Amazon are entering healthcare AI globally, per a 2026-02-11 report.
Did Kakao Healthcare hit its 2025 revenue target?
No. Internal targets cited in August 2025 aimed for ₩27 to 30 billion in FY2025 revenue, but actual FY2025 revenue came in at ₩23.1 billion, a shortfall against the company's own forecast, according to a 2026-05-15 CHA Biotech disclosure.
What is Kakao Healthcare's B2H pivot?
In April 2026, under a CHA Bio-led board restructuring, Kakao Healthcare announced a strategic shift from its consumer PASTA app toward business-to-hospital software and EHR products, aiming to use CHA's hospital network for distribution, though execution results remain unproven as of the announcement.
Timeline
  • 2026-06-22Announced chronic-disease insurance partnership with Lotte Non-Life Insurance
  • 2026-05-28CEO touts world-first Mallya insulin pen integration, plans July agentic AI update
  • 2026-05-15CHA Biotech reports Q1 2026 consolidated operating loss more than doubled to ₩30.7bn
  • 2026-04-14Post-rights-offering ownership expected: CHA ~43%, Kakao ~30%, outside investors ~27%
  • 2026-04-13Board restructured under CHA Bio, company pivots from B2C to B2H and EHR
  • 2026-04-01PASTA adds blood pressure tracking via SkyLabs CART BP device
  • 2026-02-11Report says PASTA generates about 70% of total company revenue
  • 2026-02-02Launched NovoFitCare GLP-1 obesity support feature with Novo Nordisk Korea
  • 2025-11-30Kakao Corp sells management control to CHA Hospital and Bio Group
  • 2024-02-01PASTA launches for blood glucose management with Dexcom G7 integration
Revision history
30 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources